UroGen Pharma Ltd. Increase Decrease In Operating Lease Liability
UroGen Pharma Ltd. (URGN) reported Increase Decrease In Operating Lease Liability of -$113.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-05
- UroGen Pharma Ltd. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$60.00K.
- UroGen Pharma Ltd. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$53.00K.
- UroGen Pharma Ltd. increase decrease in operating lease liability for the quarter ending 2025-12-31 was $1.33M.
- UroGen Pharma Ltd. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$628.00K.
- UroGen Pharma Ltd. increase decrease in operating lease liability for fiscal 2025 was -$639.00K.
- UroGen Pharma Ltd. increase decrease in operating lease liability for fiscal 2024 was -$1.03M.
- UroGen Pharma Ltd. increase decrease in operating lease liability for fiscal 2023 was -$987.00K.
- UroGen Pharma Ltd. increase decrease in operating lease liability for fiscal 2022 was -$1.13M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$60.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$113.00K 10-Q · filed 2026-08-05 | $1.22M derived: sum of 3 quarters · filed 2026-08-05 | $592.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$53.00K 10-Q · filed 2026-05-06 | $1.28M derived: sum of 2 quarters · filed 2026-05-06 | $652.00K derived: sum of 3 quarters · filed 2026-05-06 | $46.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $705.00K derived: sum of 2 quarters · filed 2026-03-02 | $99.00K derived: sum of 3 quarters · filed 2026-08-05 | -$639.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | -$628.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.23M derived: sum of 2 quarters · filed 2026-08-05 | -$1.97M 10-Q · filed 2025-11-06 | -$2.38M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$606.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.34M 10-Q · filed 2026-08-05 | -$1.75M derived: sum of 3 quarters · filed 2026-08-05 | -$1.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$738.00K 10-Q · filed 2026-05-06 | -$1.15M derived: sum of 2 quarters · filed 2026-05-06 | -$1.33M derived: sum of 3 quarters · filed 2026-05-06 | -$1.52M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$408.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$592.00K derived: sum of 2 quarters · filed 2026-03-02 | -$787.00K derived: sum of 3 quarters · filed 2026-03-02 | -$1.03M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$184.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$379.00K derived: sum of 2 quarters · filed 2025-11-06 | -$626.00K 10-Q · filed 2025-11-06 | -$847.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$195.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$442.00K 10-Q · filed 2025-08-07 | -$663.00K derived: sum of 3 quarters · filed 2025-08-07 | -$925.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$247.00K 10-Q · filed 2025-05-12 | -$468.00K derived: sum of 2 quarters · filed 2025-05-12 | -$730.00K derived: sum of 3 quarters · filed 2025-05-12 | -$982.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$221.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$483.00K derived: sum of 2 quarters · filed 2024-11-06 | -$735.00K derived: sum of 3 quarters · filed 2024-11-06 | -$987.00K 10-K · filed 2024-03-14 |
| 2023-09-30 | -$262.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$514.00K derived: sum of 2 quarters · filed 2024-11-06 | -$766.00K 10-Q · filed 2024-11-06 | -$1.03M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$252.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$504.00K 10-Q · filed 2024-08-13 | -$773.00K derived: sum of 3 quarters · filed 2024-08-13 | -$1.05M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$252.00K 10-Q · filed 2024-05-13 | -$521.00K derived: sum of 2 quarters · filed 2024-05-13 | -$803.00K derived: sum of 3 quarters · filed 2024-05-13 | -$1.09M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$269.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$551.00K derived: sum of 2 quarters · filed 2024-03-14 | -$839.00K derived: sum of 3 quarters · filed 2024-03-14 | -$1.13M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$282.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$570.00K derived: sum of 2 quarters · filed 2023-11-14 | -$856.00K 10-Q · filed 2023-11-14 | -$1.12M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$288.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$574.00K 10-Q · filed 2023-08-10 | -$836.00K derived: sum of 3 quarters · filed 2023-08-10 | -$1.10M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$286.00K 10-Q · filed 2023-05-11 | -$548.00K derived: sum of 2 quarters · filed 2023-05-11 | -$810.00K derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$262.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$524.00K derived: sum of 2 quarters · filed 2023-03-24 | -$1.18M 10-K · filed 2023-03-24 | |
| 2021-09-30 | -$262.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$914.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | -$652.00K 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |